www.youtube.com
April 3, 2026 at 9:47 PM
Eight public biotechs raised a total of >$3.2 billion overnight. Most had strong data readouts in the past few days. All but one upsized their offerings from their proposed targets. They say a healthy follow-on market augurs a healthy IPO market. $GPCR $WVE $DYN $VERA $FULC $KYMR $TERN $DNLI
December 10, 2025 at 1:32 PM
Eight public biotechs raised a total of >$3.2 billion overnight. Most had strong data readouts in the past few days. All but one upsized their offerings from their proposed targets. They say a healthy follow-on market augurs a healthy IPO market. $GPCR $WVE $DYN $VERA $FULC $KYMR $TERN $DNLI
literally half the accounts on vent used to say shit like “DNLI he/him lesbian supporter 😤” there is no universal dni consensus
November 12, 2024 at 10:17 PM
literally half the accounts on vent used to say shit like “DNLI he/him lesbian supporter 😤” there is no universal dni consensus
Denali Therapeutics ($DNLI) reported EPS of -0.69 beating estimate of -0.71 for Q1 2026. Revenue 0.0 Vs 3.817848 Million expected.
https://fundspec.vembar.io/DNLI
Get the most comprehensive financial analysis on the FundSpec App available on the AppStore or PlayStore!
https://fundspec.vembar.io/DNLI
Get the most comprehensive financial analysis on the FundSpec App available on the AppStore or PlayStore!
May 7, 2026 at 10:00 PM
Denali Therapeutics ($DNLI) reported EPS of -0.69 beating estimate of -0.71 for Q1 2026. Revenue 0.0 Vs 3.817848 Million expected.
https://fundspec.vembar.io/DNLI
Get the most comprehensive financial analysis on the FundSpec App available on the AppStore or PlayStore!
https://fundspec.vembar.io/DNLI
Get the most comprehensive financial analysis on the FundSpec App available on the AppStore or PlayStore!
#DNLI Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
https://www.stocktitan.net/news/DNLI/denali-therapeutics-reports-fourth-quarter-and-full-year-2025-cxlfj1zh69wa.html
https://www.stocktitan.net/news/DNLI/denali-therapeutics-reports-fourth-quarter-and-full-year-2025-cxlfj1zh69wa.html
Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
Denali Therapeutics (Nasdaq: DNLI) reported fourth quarter and full year 2025 results and program updates on Feb 26, 2026. Key items include commercial launch readiness for tividenofusp alfa ahead of an April 5, 2026 PDUFA date and clinical progress across multiple TransportVehicle platform programs.Other highlights: preliminary Phase 1/2 DNL126 data support an accelerated approval path, IND/CTA clearances and start-up for DNL952 and DNL628, a $275.0 million synthetic royalty deal with Royalty Pharma, a ~ $200.0 million net public offering, and cash and marketable securities of approximately $966.2 million as of Dec 31, 2025.
www.stocktitan.net
February 26, 2026 at 9:01 PM
#DNLI Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
https://www.stocktitan.net/news/DNLI/denali-therapeutics-reports-fourth-quarter-and-full-year-2025-cxlfj1zh69wa.html
https://www.stocktitan.net/news/DNLI/denali-therapeutics-reports-fourth-quarter-and-full-year-2025-cxlfj1zh69wa.html
For you to share with your children. The moral of the fable is,
Trump and his own sour grapes. 🤣 Trump is such a fool.
www.youtube.com/watch?v=Dnli...
Trump and his own sour grapes. 🤣 Trump is such a fool.
www.youtube.com/watch?v=Dnli...
June 1, 2026 at 4:50 AM
For you to share with your children. The moral of the fable is,
Trump and his own sour grapes. 🤣 Trump is such a fool.
www.youtube.com/watch?v=Dnli...
Trump and his own sour grapes. 🤣 Trump is such a fool.
www.youtube.com/watch?v=Dnli...
#DNLI Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa
https://www.stocktitan.net/news/DNLI/denali-therapeutics-announces-primary-analysis-and-long-term-follow-hoqxyf9q4mos.html
https://www.stocktitan.net/news/DNLI/denali-therapeutics-announces-primary-analysis-and-long-term-follow-hoqxyf9q4mos.html
Clinical Trial Success: Denali's Hunter Syndrome Drug Delivers Game-Changing Patient Improvements
Denali's tividenofusp alfa demonstrates sustained improvements in hearing, cognition, and behavior for Hunter syndrome patients, with BLA submission planned for early 2025.
www.stocktitan.net
February 6, 2025 at 4:42 PM
#DNLI Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa
https://www.stocktitan.net/news/DNLI/denali-therapeutics-announces-primary-analysis-and-long-term-follow-hoqxyf9q4mos.html
https://www.stocktitan.net/news/DNLI/denali-therapeutics-announces-primary-analysis-and-long-term-follow-hoqxyf9q4mos.html
Normally, I try to avoid talking about politics on social media, but this right here is some delicious irony.
www.instagram.com/reel/DNLi-6U...
www.instagram.com/reel/DNLi-6U...
Instagram
Create an account or log in to Instagram - Share what you're into with the people who get you.
www.instagram.com
August 14, 2025 at 3:20 PM
Normally, I try to avoid talking about politics on social media, but this right here is some delicious irony.
www.instagram.com/reel/DNLi-6U...
www.instagram.com/reel/DNLi-6U...
#$DNLI, #$BIIB - Experimental Parkinson’s drug BIIB122 failed to slow disease in trials despite strong biological effects; development stopped. notreload.xyz/xy/biogen-de...
Biogen and Denali Halt BIIB122 After Parkinson’s Phase 2 Failure
Experimental Parkinson’s drug BIIB122 failed to slow disease in trials despite strong biological effects; development stopped.
notreload.xyz
May 22, 2026 at 12:30 PM
#$DNLI, #$BIIB - Experimental Parkinson’s drug BIIB122 failed to slow disease in trials despite strong biological effects; development stopped. notreload.xyz/xy/biogen-de...
BREAKING NEWS: ( NASDAQ: #DNLI ) Denali Therapeutics Announces Successful Meeting with the FDA and Plans to File for Accelerated Approval of Tividenofusp Alfa (DNL310) for the Treatment of MPS II (Hunter Syndrome)
#StockMarket #News
#StockMarket #News
September 3, 2024 at 5:45 PM
$DNLI-1 $QUBT-1 $HOOG-1 $SPRY-1 $MCHP-1 $ASAN-1 $GILT-1 $FLY-1 $TLK-1 $IJR-1 $AAP-1 $XENE-1 $BNO-1 $UPRO-1 $OMC-1 $FSLY-1 $LUMN-1 $SOXS-1 $LABD-1 $ORCX-1 $CORZ-1 $UDOW-1
Daily Wrap - Final Message: Daily Wrap up for 2026-06-26 - 1842 events.
#burst_trades #HFT #trading ...
Daily Wrap - Final Message: Daily Wrap up for 2026-06-26 - 1842 events.
#burst_trades #HFT #trading ...
June 26, 2026 at 8:19 PM
$DNLI-1 $QUBT-1 $HOOG-1 $SPRY-1 $MCHP-1 $ASAN-1 $GILT-1 $FLY-1 $TLK-1 $IJR-1 $AAP-1 $XENE-1 $BNO-1 $UPRO-1 $OMC-1 $FSLY-1 $LUMN-1 $SOXS-1 $LABD-1 $ORCX-1 $CORZ-1 $UDOW-1
Daily Wrap - Final Message: Daily Wrap up for 2026-06-26 - 1842 events.
#burst_trades #HFT #trading ...
Daily Wrap - Final Message: Daily Wrap up for 2026-06-26 - 1842 events.
#burst_trades #HFT #trading ...
Getting medicines into the brain: shuttles, vectors and direct delivery | #$DNLI, #$QURE, #$RHHBY, #$VYGR
www.merlintrader.com/brain-drug-d...
www.merlintrader.com/brain-drug-d...
September 26, 2026 at 10:38 AM
Getting medicines into the brain: shuttles, vectors and direct delivery | #$DNLI, #$QURE, #$RHHBY, #$VYGR
www.merlintrader.com/brain-drug-d...
www.merlintrader.com/brain-drug-d...
🔴 #DNLI — Thornberry Nancy, Director
SOLD: 10,824 shares @ $22.85
Total: $247K
Filed Sep 1, 2026 · 8:00pm ET
📈 History & trend → https://www.formdelta.com/ticker/DNLI
#InsiderTrading #DNLI #StockMarket
SOLD: 10,824 shares @ $22.85
Total: $247K
Filed Sep 1, 2026 · 8:00pm ET
📈 History & trend → https://www.formdelta.com/ticker/DNLI
#InsiderTrading #DNLI #StockMarket
FormDelta — Insider Trading Alerts
Thornberry Nancy just sold $247K in DNLI. Track all SEC Form 4 insider trades in real-time.
www.formdelta.com
September 4, 2026 at 9:09 PM
🔴 #DNLI — Thornberry Nancy, Director
SOLD: 10,824 shares @ $22.85
Total: $247K
Filed Sep 1, 2026 · 8:00pm ET
📈 History & trend → https://www.formdelta.com/ticker/DNLI
#InsiderTrading #DNLI #StockMarket
SOLD: 10,824 shares @ $22.85
Total: $247K
Filed Sep 1, 2026 · 8:00pm ET
📈 History & trend → https://www.formdelta.com/ticker/DNLI
#InsiderTrading #DNLI #StockMarket
📄 #DNLI 10-Q — what changed
MD&A now says: "Forward-looking statements include, but are not limited to, statements about: • the commercial success of AVLAYAH and any other products for which we obtain marketing approval; • the progress, success, cost, and timing of our development activ
MD&A now says: "Forward-looking statements include, but are not limited to, statements about: • the commercial success of AVLAYAH and any other products for which we obtain marketing approval; • the progress, success, cost, and timing of our development activ
FormDelta — Insider Trading Alerts
What Denali Therapeutics Inc. changed in their own words, quarter over quarter.
www.formdelta.com
September 4, 2026 at 9:09 PM
Denali Therapeutics $DNLI: B. Riley Securities raised its price target from $30.00 to $35.00 and maintained its Buy rating.
https://fundspec.ai/s/DNLI/analysts
Track what company insiders are actually buying and selling.
https://fundspec.ai/s/DNLI/analysts
Track what company insiders are actually buying and selling.
August 25, 2026 at 6:15 PM
Denali Therapeutics $DNLI: B. Riley Securities raised its price target from $30.00 to $35.00 and maintained its Buy rating.
https://fundspec.ai/s/DNLI/analysts
Track what company insiders are actually buying and selling.
https://fundspec.ai/s/DNLI/analysts
Track what company insiders are actually buying and selling.
🚨 $DNLI
Watts Ryan J. (President and CEO) reported special transactions (Non-P/S).
Watts Ryan J. (President and CEO) reported special transactions (Non-P/S).
SEC Filing: DNLI
Click to view the official SEC document.
www.sec.gov
August 14, 2026 at 9:03 PM
🚨 $DNLI
Watts Ryan J. (President and CEO) reported special transactions (Non-P/S).
Watts Ryan J. (President and CEO) reported special transactions (Non-P/S).
🚨 $DNLI
Schuth Alexander O. (COFO and Secretary) sold 2,857 shares at an average price of $25.0700 per common share. (Date: 2026-08-11)
Schuth Alexander O. (COFO and Secretary) sold 2,857 shares at an average price of $25.0700 per common share. (Date: 2026-08-11)
SEC Filing: DNLI
Click to view the official SEC document.
www.sec.gov
August 13, 2026 at 9:15 PM
🚨 $DNLI
Schuth Alexander O. (COFO and Secretary) sold 2,857 shares at an average price of $25.0700 per common share. (Date: 2026-08-11)
Schuth Alexander O. (COFO and Secretary) sold 2,857 shares at an average price of $25.0700 per common share. (Date: 2026-08-11)
🚨 $DNLI
Schuth Alexander O., a Officer, filed a notice of intent to sell 2,857 shares of common stock, valued at approximately $71,623.51, on 08/11/2026.
Schuth Alexander O., a Officer, filed a notice of intent to sell 2,857 shares of common stock, valued at approximately $71,623.51, on 08/11/2026.
SEC Filing: DNLI
Click to view the official SEC document.
www.sec.gov
August 11, 2026 at 10:07 PM
🚨 $DNLI
Schuth Alexander O., a Officer, filed a notice of intent to sell 2,857 shares of common stock, valued at approximately $71,623.51, on 08/11/2026.
Schuth Alexander O., a Officer, filed a notice of intent to sell 2,857 shares of common stock, valued at approximately $71,623.51, on 08/11/2026.
The Manufacturers Life Insurance Company Reduces Stock Holdings in Denali Therapeutics Inc. $DNLI
The Manufacturers Life Insurance Company lessened its position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 31.9% in the 1st quarter, according to its most recent filing with…
The Manufacturers Life Insurance Company lessened its position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 31.9% in the 1st quarter, according to its most recent filing with…
The Manufacturers Life Insurance Company Reduces Stock Holdings in Denali Therapeutics Inc. $DNLI
The Manufacturers Life Insurance Company lessened its position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 31.9% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 125,442 shares of the company’s stock after selling 58,796 shares during the quarter. The Manufacturers Life [...]
news-area.com
August 9, 2026 at 9:28 PM
The Manufacturers Life Insurance Company Reduces Stock Holdings in Denali Therapeutics Inc. $DNLI
The Manufacturers Life Insurance Company lessened its position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 31.9% in the 1st quarter, according to its most recent filing with…
The Manufacturers Life Insurance Company lessened its position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 31.9% in the 1st quarter, according to its most recent filing with…
Denali's AVLAYAH Launch Generates $3.6M, Exceeding Expectations Amid Pipeline Setbacks https://signalbloom.ai/news/DNLI/denalis-avlayah-launch-generates-36m-exceeding-expectations-amid-pipeline-setbacks $DNLI #Earnings via @signalbloom.ai
August 6, 2026 at 8:09 PM
Denali's AVLAYAH Launch Generates $3.6M, Exceeding Expectations Amid Pipeline Setbacks https://signalbloom.ai/news/DNLI/denalis-avlayah-launch-generates-36m-exceeding-expectations-amid-pipeline-setbacks $DNLI #Earnings via @signalbloom.ai
Denali Therapeutics ($DNLI) reported EPS of -0.68 missing estimate of -0.57 for Q2 2026. Revenue 3.604 Million Vs 2.033976 Million expected.
https://fundspec.ai
Build custom AI trading models for DNLI with the FundSpec App!
https://fundspec.ai
Build custom AI trading models for DNLI with the FundSpec App!
August 6, 2026 at 8:09 PM
Denali Therapeutics ($DNLI) reported EPS of -0.68 missing estimate of -0.57 for Q2 2026. Revenue 3.604 Million Vs 2.033976 Million expected.
https://fundspec.ai
Build custom AI trading models for DNLI with the FundSpec App!
https://fundspec.ai
Build custom AI trading models for DNLI with the FundSpec App!
🚨 $DNLI
On August 6, 2026, Denali Therapeutics Inc. issued a press release announcing its financial results for the second quarter ended June 30, 2026. The full text of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
On August 6, 2026, Denali Therapeutics Inc. issued a press release announcing its financial results for the second quarter ended June 30, 2026. The full text of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
SEC Filing: DNLI
Click to view the official SEC document.
www.sec.gov
August 6, 2026 at 8:09 PM
🚨 $DNLI
On August 6, 2026, Denali Therapeutics Inc. issued a press release announcing its financial results for the second quarter ended June 30, 2026. The full text of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
On August 6, 2026, Denali Therapeutics Inc. issued a press release announcing its financial results for the second quarter ended June 30, 2026. The full text of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
#DNLI Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights
https://www.stocktitan.net/news/DNLI/denali-therapeutics-reports-second-quarter-2026-financial-results-wdg4eefs3ozv.html
https://www.stocktitan.net/news/DNLI/denali-therapeutics-reports-second-quarter-2026-financial-results-wdg4eefs3ozv.html
Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights
Denali Therapeutics (Nasdaq: DNLI) reported second-quarter 2026 net product revenue of $3.6 million, driven by the first full quarter of the U.S. launch of AVLAYAH for Hunter syndrome. Net loss was $127.6 million versus $124.1 million a year earlier, with R&D expenses of $97.0 million and SG&A of $36.3 million.According to Denali, third-quarter 2026 AVLAYAH net product revenue is projected at $10–12 million. Cash, cash equivalents and marketable securities totaled about $940 million at June 30, 2026; pro forma liquidity exceeds $1.1 billion after receiving $195 million from the sale of a Priority Review Voucher in July 2026.Denali advanced its TransportVehicle portfolio, including AVLAYAH’s ongoing Phase 2/3 COMPASS confirmatory study, Phase 3 start-up for zafinofusp alfa in Sanfilippo syndrome type A with a planned 2027 BLA, and multiple investigational programs in lysosomal storage diseases, Alzheimer’s disease and frontotemporal dementia.
www.stocktitan.net
August 6, 2026 at 8:01 PM
#DNLI Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights
https://www.stocktitan.net/news/DNLI/denali-therapeutics-reports-second-quarter-2026-financial-results-wdg4eefs3ozv.html
https://www.stocktitan.net/news/DNLI/denali-therapeutics-reports-second-quarter-2026-financial-results-wdg4eefs3ozv.html
$DNLI — Major Shareholder
Baillie Gifford & Co filed an amended Schedule 13G with the SEC on August 4, 2026, reporting beneficial ownership of 11,960,230 shares of Denali Therapeutics Inc. common stock, representing 7.54% of the outstanding shares as of June 30, 2026.
🧵 continued ↓
Baillie Gifford & Co filed an amended Schedule 13G with the SEC on August 4, 2026, reporting beneficial ownership of 11,960,230 shares of Denali Therapeutics Inc. common stock, representing 7.54% of the outstanding shares as of June 30, 2026.
🧵 continued ↓
August 4, 2026 at 8:45 PM
$DNLI — Major Shareholder
Baillie Gifford & Co filed an amended Schedule 13G with the SEC on August 4, 2026, reporting beneficial ownership of 11,960,230 shares of Denali Therapeutics Inc. common stock, representing 7.54% of the outstanding shares as of June 30, 2026.
🧵 continued ↓
Baillie Gifford & Co filed an amended Schedule 13G with the SEC on August 4, 2026, reporting beneficial ownership of 11,960,230 shares of Denali Therapeutics Inc. common stock, representing 7.54% of the outstanding shares as of June 30, 2026.
🧵 continued ↓
Time to officially change the name of the DNI to DNLI or Director of Lack of Intelligence? It both reflects the lack of any intellect by the director and the inability for any foreign government to collaborate with such inept leadership.
July 29, 2026 at 6:18 PM
Time to officially change the name of the DNI to DNLI or Director of Lack of Intelligence? It both reflects the lack of any intellect by the director and the inability for any foreign government to collaborate with such inept leadership.